Connect
MJA
MJA

Subsidised access to TNFα inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

Christine Y Lu, Kenneth M Williams, Lyn March, James V Bertouch and Richard O Day
Med J Aust 2004; 181 (8): 457-458.
Published online: 18 October 2004

Christine Y Lu,* Kenneth M Williams,† Lyn March,‡ James V Bertouch,§ Richard O Day¶

  • Christine Y Lu1
  • Kenneth M Williams1
  • Lyn March2
  • James V Bertouch3
  • Richard O Day3

  • 2 Therapeutics Centre, St Vincent’s Hospital, University of New South Wales, Victoria St, Darlinghurst, Sydney, NSW 2010.
  • 3 Royal North Shore Hospital, The University of Sydney, St Leonards, NSW.
  • 4 Department of Rheumatology, Prince of Wales Hospital, Randwick, NSW.


Competing interests:

Richard Day is a member of the Advisory Board to sponsors of adalimumab and infliximab, but all payments are received into an audited trust account for research. Ken Williams is a member of the Advisory Board and has been an advisor to the sponsor of adalimumab (Abbott), but has not received recompense. Lyn March is chairperson of the Australian Rheumatology Association Database Steering Committee and, in this capacity, has negotiated with sponsors of etanercept, adalimumab, infliximab, anakinra and leflunomide for educational grants that have been placed in audited trust funds in the Australian Rheumatology Association and the University of Sydney. James Bertouch has been an advisor to sponsors of adalimumab, infliximab, etanercept, anakinra and leflunomide. Recompense received for clinical trials has been placed in audited hospital trust funds for use in the research activities of the Rheumatology Unit, Prince of Wales Hospital, Sydney.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.